ACTR8

Across TCGA pan-cancer cohorts, ACTR8 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ACTR8’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ACTR8 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACTR8 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, KIRC, and COAD are the cancer types where ACTR8 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTR8 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.074	<.001	9	view →
KIRC	Male	III,IV	−0.643	<.001	9	view →
COAD	Male	All	+0.445	<.001	8	view →
KICH	All	All	−0.585	.001	4	view →
STAD	All	II,III,IV	+0.551	.003	4	view →
CHOL	Male	All	+1.608	<.001	3	view →
LUAD	All	All	+0.181	.004	3	view →
LUSC	Female	III,IV	−0.599	.042	1	view →
KIRP	Female	All	+0.596	.035	1	view →
THCA	All	All	−0.231	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ACTR8–LIHC

Open the LIHC breakdown →